Author

M. G. Kirkpatrick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 3 Assay:proteomics· 1 Organism:virus· 1

Frequent Co-Authors

A. K. Chatterjee· 3 shared C. W. McNamara· 3 shared M. A. Bakowski· 3 shared N. Beutler· 3 shared A. Gebara-Lamb· 2 shared A. K. Gupta· 2 shared E. Chen· 2 shared K. C. Wolff· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. K. Chatterjee

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

High Throughput Screening with a Primary Human Mucociliary Airway Model Identifies a Small Molecule with Anti-SARS-CoV-2 Activity

C. Sen, T. M. Rickabaugh, A. V. Jeyachandran, C. Yuen, M. Ghannam, A. Durra, A. Aziz, K. Castillo, G. Garcia, A. Purkayastha, B. Han, F. W. Boulton, E. Chekler, R. Garces, K. C. Wolff, , B. Gomperts

This study uses a primary human stem cell-based airway model to screen 2100 compounds and identifies a small molecule effective against SARS-CoV-2 and its Omicron variant.

bioRxiv · May 9, 2024 · PreprintCell Biology

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead

N. G. R. D. Elshan, K. C. Wolff, L. Riva, A. K. Woods, G. Grabovyi, K. Wilson, A. Rahimi, J. Pedroarena, S. Ghorai, A. K. Gupta, A. Nazarian, F. Weiss, Y. Liu, W. Mazumdar, L. Song, , A. K. Chatterjee

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

bioRxiv · Oct 24, 2023Microbiology

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19

M. A. Bakowski, N. Beutler, E. Chen, T.-T. H. Nguyen, M. G. Kirkpatrick, M. Parren, L. Yang, J. Ricketts, A. K. Gupta, M. V. Hull, P. G. Schultz, D. R. Burton, A. K. Chatterjee, C. W. McNamara, T. F. Rogers

The paper identifies 66 compounds that inhibit SARS-CoV-2 replication and 24 that synergize with remdesivir, suggesting potential oral drug repositioning candidates for COVID-19.

Nature Communications · Jun 3, 2021Peer-reviewedMicrobiology

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

B. Boras, R. M. Jones, B. J. Anson, D. Arenson, L. Aschenbrenner, M. A. Bakowski, N. Beutler, J. Binder, E. Chen, H. Eng, J. Hammond, R. Hoffman, E. P. Kadar, R. Kania, E. Kimoto, , M. E. McGrath

This study identifies PF-00835321 as a potent inhibitor of SARS-CoV-2 3CL protease with in vitro antiviral activity and clinical evaluation potential.

bioRxiv · Sep 12, 2020 · PreprintPharmacology & Toxicology